Aurinia Pharmaceuticals Inc. provided earnings guidance for the fiscal year 2023. For the period, the company is narrowing its net product revenue guidance to a range of $155 million - $160 million for net product sales of LUPKYNIS. This guidance range is based on assumptions regarding PSF run rates, consistent conversion rates, time to convert, persistency and pricing.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.31 USD | +2.12% | +3.11% | -40.93% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-40.93% | 758M | |
+7.52% | 113B | |
+11.38% | 106B | |
-12.64% | 22.22B | |
+0.44% | 22.27B | |
-4.18% | 19.43B | |
-37.85% | 17.87B | |
-8.58% | 17.24B | |
+37.41% | 12.52B | |
-23.95% | 8.34B |
- Stock Market
- Equities
- AUPH Stock
- News Aurinia Pharmaceuticals Inc.
- Aurinia Pharmaceuticals Inc. Provides Earnings Guidance for the Fiscal Year 2023